Approaches Towards Biomaterial-mediated Gene Editing for Cancer Immunotherapy

Overview

Journal Biomater Sci

Publisher Royal Society of Chemistry

Specialties Biomedical Engineering
Pharmacology

Date 2022 Jul 20

PMID 35858470

Authors

Sydney R Shannon

Elana Ben-Akiva

Jordan J Green

Affiliations

Soon will be listed here.

Abstract

Gene therapies are transforming treatment modalities for many human diseases and disorders, including those in ophthalmology, oncology, and nephrology. To maximize the clinical efficacy and safety of these treatments, consideration of both delivery materials and cargos is critical. In consideration of the former, a large effort has been placed on transitioning away from potentially immunoreactive and toxic viral delivery mechanisms towards safer and highly tunable nonviral delivery mechanisms, including polymeric, lipid-based, and inorganic carriers. This change of paradigm does not come without obstacles, as efficient non-viral delivery is challenging, particularly to immune cells, and has yet to see clinical translation breakthroughs for gene editing. This mini-review describes notable examples of biomaterial-based gene delivery to immune cells, with emphasis on recent successes. In consideration of delivery cargos, clustered regularly interspaced palindromic repeat (CRISPR) technology is reviewed and its great promise in the field of immune cell gene editing is described. This mini-review describes how leading non-viral delivery materials and CRISPR technology can be integrated together to advance its clinical potential for therapeutic gene transfer to immune cells to treat cancer.

Citing Articles

Lipid-based nanosystems: the next generation of cancer immune therapy.

Cheng Z, Fobian S, Gurrieri E, Amin M, DAgostino V, Falahati M J Hematol Oncol. 2024; 17(1):53.

PMID: 39030582 PMC: 11265205. DOI: 10.1186/s13045-024-01574-1.

References

Lou B, De Beuckelaer A, Dakwar G, Remaut K, Grooten J, Braeckmans K . Post-PEGylated and crosslinked polymeric ssRNA nanocomplexes as adjuvants targeting lymph nodes with increased cytolytic T cell inducing properties. J Control Release. 2018; 284:73-83. DOI: 10.1016/j.jconrel.2018.06.010. View

Smith T, Stephan S, Moffett H, McKnight L, Ji W, Reiman D . In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Nat Nanotechnol. 2017; 12(8):813-820. PMC: 5646367. DOI: 10.1038/nnano.2017.57. View

Rui Y, Wilson D, Choi J, Varanasi M, Sanders K, Karlsson J . Carboxylated branched poly(β-amino ester) nanoparticles enable robust cytosolic protein delivery and CRISPR-Cas9 gene editing. Sci Adv. 2019; 5(12):eaay3255. PMC: 6897553. DOI: 10.1126/sciadv.aay3255. View

Mollanoori H, Shahraki H, Rahmati Y, Teimourian S . CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment. Hum Immunol. 2018; 79(12):876-882. DOI: 10.1016/j.humimm.2018.09.007. View

Sago C, Lokugamage M, Paunovska K, Vanover D, Monaco C, Shah N . High-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editing. Proc Natl Acad Sci U S A. 2018; 115(42):E9944-E9952. PMC: 6196543. DOI: 10.1073/pnas.1811276115. View

Peer D . A daunting task: manipulating leukocyte function with RNAi. Immunol Rev. 2013; 253(1):185-97. DOI: 10.1111/imr.12044. View

Pickar-Oliver A, Gersbach C . The next generation of CRISPR-Cas technologies and applications. Nat Rev Mol Cell Biol. 2019; 20(8):490-507. PMC: 7079207. DOI: 10.1038/s41580-019-0131-5. View

Dobrovolskaia M, Bathe M . Opportunities and challenges for the clinical translation of structured DNA assemblies as gene therapeutic delivery and vaccine vectors. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020; 13(1):e1657. PMC: 7736207. DOI: 10.1002/wnan.1657. View

Billingsley M, Singh N, Ravikumar P, Zhang R, June C, Mitchell M . Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering. Nano Lett. 2020; 20(3):1578-1589. PMC: 7313236. DOI: 10.1021/acs.nanolett.9b04246. View

10.

Veiga N, Diesendruck Y, Peer D . Targeted lipid nanoparticles for RNA therapeutics and immunomodulation in leukocytes. Adv Drug Deliv Rev. 2020; 159:364-376. DOI: 10.1016/j.addr.2020.04.002. View

11.

Pennetta C, Bono N, Ponti F, Bellucci M, Viani F, Candiani G . Multifunctional Neomycin-Triazine-Based Cationic Lipids for Gene Delivery with Antibacterial Properties. Bioconjug Chem. 2021; 32(4):690-701. PMC: 8154203. DOI: 10.1021/acs.bioconjchem.0c00616. View

12.

Oliver S, Gargano J, Marin M, Wallace M, Curran K, Chamberland M . The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020. MMWR Morb Mortal Wkly Rep. 2020; 69(50):1922-1924. PMC: 7745957. DOI: 10.15585/mmwr.mm6950e2. View

13.

Rui Y, Wilson D, Sanders K, Green J . Reducible Branched Ester-Amine Quadpolymers (rBEAQs) Codelivering Plasmid DNA and RNA Oligonucleotides Enable CRISPR/Cas9 Genome Editing. ACS Appl Mater Interfaces. 2019; 11(11):10472-10480. PMC: 7309334. DOI: 10.1021/acsami.8b20206. View

14.

Wiede F, Lu K, Du X, Liang S, Hochheiser K, Dodd G . PTPN2 phosphatase deletion in T cells promotes anti-tumour immunity and CAR T-cell efficacy in solid tumours. EMBO J. 2019; 39(2):e103637. PMC: 6960448. DOI: 10.15252/embj.2019103637. View

15.

Chechik L, Martin O, Soutoglou E . Genome Editing Fidelity in the Context of DNA Sequence and Chromatin Structure. Front Cell Dev Biol. 2020; 8:319. PMC: 7225291. DOI: 10.3389/fcell.2020.00319. View

16.

Shimasaki N, Jain A, Campana D . NK cells for cancer immunotherapy. Nat Rev Drug Discov. 2020; 19(3):200-218. DOI: 10.1038/s41573-019-0052-1. View

17.

Mo F, Duan S, Jiang X, Yang X, Hou X, Shi W . Nanobody-based chimeric antigen receptor T cells designed by CRISPR/Cas9 technology for solid tumor immunotherapy. Signal Transduct Target Ther. 2021; 6(1):80. PMC: 7904846. DOI: 10.1038/s41392-021-00462-1. View

18.

Foldvari M, Chen D, Nafissi N, Calderon D, Narsineni L, Rafiee A . Non-viral gene therapy: Gains and challenges of non-invasive administration methods. J Control Release. 2015; 240:165-190. DOI: 10.1016/j.jconrel.2015.12.012. View

19.

Gan Z, Lokugamage M, Hatit M, Loughrey D, Paunovska K, Sato M . Nanoparticles containing constrained phospholipids deliver mRNA to liver immune cells in vivo without targeting ligands. Bioeng Transl Med. 2021; 5(3):e10161. PMC: 7974401. DOI: 10.1002/btm2.10161. View

20.

Al-Dosari M, Gao X . Nonviral gene delivery: principle, limitations, and recent progress. AAPS J. 2009; 11(4):671-81. PMC: 2782077. DOI: 10.1208/s12248-009-9143-y. View